Alamar Biosciences Inc

Alamar Biosciences Inc(ALMR)资讯与事件

$30.710

-2.131 (-6.94%)收盘时

ALMR 资讯

ALMR 事件

8/10 17:30

Alamar Biosciences Expands Partnership with Alzheimer's Disease Data Initiative

Alamar Biosciences announced an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. The expanded agreement adds profiling of 86,000 plasma samples using the company's newest neurology panel, NULISAseq Neuro 220. Approximately 21,000 samples are part of a national-scale proteomics initiative launched with leading research universities in mid-July. Building on the June 2025 announcement of a multi-center initiative which profiled over 55,000 samples using Alamar's ultra-sensitive NULISA technology, this expansion reflects growing confidence in the partnership's scientific output and the Neuro 220 panel's ability to deliver richer insights into the co-pathologies driving neurodegenerative disease. The combined dataset, when completed in 2027, is expected to encompass more than 140,000 samples profiled across multiple geographies and cohorts.

8/10 17:00

Alamar Biosciences Q2 Revenue $29.4M Beats Expectations

Reports Q2 revenue $29.4M, consensus $25.94M. "We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year," said Yuling Luo, CEO of Alamar Biosciences. "With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters."

8/10 17:00

Alamar Biosciences Sees FY26 Revenue of $116M-$120M

Alamar Biosciences sees FY26 revenue $116M-$120M, consensus $113.22M

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始